FGFR rearrangements: oncogenic drivers and therapeutic targets
Trends in Cancer · 2026-05 · 12 (5) · 461-476
DOI: 10.1016/j.trecan.2026.01.010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2026-05. Verfasst von Julia Yemelyanenko und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Neoplasms, Receptors, Fibroblast Growth Factor, Gene Rearrangement. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: Oncode Institute, Netherlands Ministry of Health Welfare and Sport, Dutch Cancer Society.
Abstract (Originalsprache)
Genomic amplifications and hotspot mutations affecting fibroblast growth factor receptors (FGFRs) have long been recognized as oncogenic drivers across human cancers. However, recent studies have uncovered FGFR in-frame fusions and complex structural variants as an additional class of tumor driver alterations. Notably, the identification of FGFR2 exon 18 truncations and the demonstration of their potent oncogenic competence have refined our understanding of FGFR-driven tumorigenesis and have impacted clinical trial design for FGFR-targeted agents. This review explores the biological and clinical implications of FGFR rearrangements. It covers their mechanisms in driving cancer, their potential as biomarkers to predict treatment response, and the emerging challenges and opportunities for FGFR-targeted therapy. Ultimately, a deeper understanding of FGFR rearrangements is critical for advancing precision oncology and improving patient benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
- Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands. Electronic address: j.jonkers@nki.nl.
- Department of Discovery Oncology, Genentech, Inc., South San Francisco, CA, USA. Electronic address: zingg.daniel@gene.com.
Förderung
- Oncode Institute
- Netherlands Ministry of Health Welfare and Sport
- Dutch Cancer Society
Zitieren
APA
Yemelyanenko, J., Jonkers, J., & Zingg, D. (2026). FGFR rearrangements: oncogenic drivers and therapeutic targets. Trends in Cancer, 12(5), 461-476. https://doi.org/10.1016/j.trecan.2026.01.010
Vancouver
Yemelyanenko J, Jonkers J, Zingg D. FGFR rearrangements: oncogenic drivers and therapeutic targets. Trends in Cancer. 2026;12(5):461-476. doi:10.1016/j.trecan.2026.01.010
BibTeX
@article{Yemelyanenko2026,
author = {Yemelyanenko, Julia and Jonkers, Jos and Zingg, Daniel},
title = {FGFR rearrangements: oncogenic drivers and therapeutic targets},
journal = {Trends in Cancer},
year = {2026},
volume = {12},
number = {5},
pages = {461--476},
doi = {10.1016/j.trecan.2026.01.010}
}
EUVIMED